日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

TAK-264 (MLN0264) 用于既往接受过治疗的表达鸟苷酸环化酶 C 的晚期胃肠道癌亚洲患者:一项开放标签、非随机 1 期研究的结果

Bang, Yung-Jue; Takano, Toshimi; Lin, Chia-Chi; Fasanmade, Adedigbo; Yang, Huyuan; Danaee, Hadi; Asato, Takayuki; Kalebic, Thea; Wang, Hui; Doi, Toshihiko

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

英夫利昔单抗联合甲氨蝶呤治疗多关节型幼年类风湿性关节炎的长期疗效和安全性:一项开放标签治疗扩展研究的结果

Ruperto, Nicolino; Lovell, Daniel J; Cuttica, Ruben; Woo, Patricia; Meiorin, Silvia; Wouters, Carine; Silverman, Earl D; Balogh, Zsolt; Henrickson, Michael; Davidson, Joyce; Foeldvari, Ivan; Imundo, Lisa; Simonini, Gabriele; Oppermann, Joachim; Xu, Stephen; Shen, Yaung-Kaung; Visvanathan, Sudha; Fasanmade, Adedigbo; Mendelsohn, Alan; Martini, Alberto; Giannini, Edward H

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

英夫利昔单抗在溃疡性结肠炎患者中的群体药代动力学分析

Fasanmade, Adedigbo A; Adedokun, Omoniyi J; Ford, Joyce; Hernandez, Danika; Johanns, Jewel; Hu, Chuanpu; Davis, Hugh M; Zhou, Honghui